From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
Clinical data
Trade namesTakhzyro
Routes of
Subcutaneous injection
ATC code
Legal status
Legal status
CAS Number
  • none
Chemical and physical data
Molar mass145.7 kDa g·mol−1

Lanadelumab (INN) (trade name Takhzyro) is a human monoclonal antibody (class IgG1 kappa)[1] that targets plasma kallikrein (pKal)[2] in order to promote prevention of angioedema in patients with hereditary angioedema.[3][4] In phase 1 clinical trials Lanadelumab was well tolerated and was reported to reduce cleavage of kininogen in the plasma of patients with hereditary angioedema and decrease the number of patients experiencing attacks of angioedema.[2][5][6][7] As of 2017 ongoing trials for Lanadelumab include two phase 3 studies focused on investigating the utility of Lanadelumab in preventing of acute angioedema attacks in hereditary angioedema patients[8][9]

This drug was produced by Dyax Corp and currently under development by Shire.[10] Lanadelumab has been designated by the U.S. Food and Drug Administration (FDA) as a breakthrough therapy.[11]


  1. ^ Kenniston, Jon A.; Faucette, Ryan R.; Martik, Diana; Comeau, Stephen R.; Lindberg, Allison P.; Kopacz, Kris J.; Conley, Gregory P.; Chen, Jie; Viswanathan, Malini (2014-08-22). "Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody". The Journal of Biological Chemistry. 289 (34): 23596. doi:10.1074/jbc.M114.569061. PMC 4156074. PMID 24970892.
  2. ^ a b Banerji, Aleena; Busse, Paula; Shennak, Mustafa; Lumry, William; Davis-Lorton, Mark; Wedner, Henry J.; Jacobs, Joshua; Baker, James; Bernstein, Jonathan A. (2017-02-23). "Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis". The New England Journal of Medicine. 376 (8): 717–728. doi:10.1056/NEJMoa1605767. ISSN 1533-4406. PMID 28225674.
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lanadelumab, American Medical Association.
  4. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
  5. ^ Chyung, Yung; Vince, Bradley; Iarrobino, Ryan; Sexton, Dan; Kenniston, Jon; Faucette, Ryan; TenHoor, Chris; Stolz, Leslie E.; Stevens, Chris (2014-10-01). "A phase 1 study investigating DX-2930 in healthy subjects". Annals of Allergy, Asthma & Immunology. 113 (4): 460–466.e2. doi:10.1016/j.anai.2014.05.028. ISSN 1534-4436. PMID 24980392.
  6. ^ "A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects - Full Text View -". Retrieved 2017-03-24.
  7. ^ "Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects - Full Text View -". Retrieved 2017-03-24.
  8. ^ "Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE - Full Text View -". Retrieved 2017-03-24.
  9. ^ "Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE - Full Text View -". Retrieved 2017-03-24.
  10. ^ "Lanadelumab - AdisInsight". Retrieved 2017-03-24.
  11. ^ "Dyax Corp. Receives FDA Breakthrough Therapy Designation for DX-2930 for Prevention of Attacks of Hereditary Angioedema". Retrieved 2017-03-24.